Sentences with phrase «novel therapies with»

Not exact matches

On August 30, the U.S. Food and Drug Administration approved a novel gene therapy for patients with a rare type of leukemia.

Using a novel form of gene therapy, scientists from Harvard Medical School and the Massachusetts General Hospital have managed to restore partial hearing and balance in mice born with a genetic condition that affects both.

A novel psychological therapy that encourages addressing emotional experiences related to trauma, conflict and relationship problems has been found helpful for people with the chronic pain condition fibromyalgia.

While she does not believe music would replace current epilepsy therapy, Charyton said this research suggests music might be a novel intervention used in conjunction with traditional treatment to help prevent seizures in people with epilepsy.

«It is anticipated that this novel compound will have significant efficacy in human melanomas and other cancers either as a stand - alone therapy or in combination with other targeted or immune - based therapies,» explained co-corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine (BUSM).

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

«Novel diet therapy helps children with crohn's disease and ulcerative colitis reach remission.»

«We wanted to develop a novel strategy with PET imaging for non-invasively determining EGFR mutation status in real - time, predict NSCLC patients who may benefit from EGFR - TKI therapy, and monitor EGFR - TKI treatment outcome.»

The clinical trial results, published online in the Journal of Allergy and Clinical Immunology: In Practice, suggest that Verapamil represents a promising novel therapy for the treatment of CRS with nasal polyps.

This could lead to novel therapies to help patients with MS and many other diseases associated with myelin.

PIND's goal is an integrated, interdisciplinary approach to the study of neurodegenerative diseases and their mechanisms, with the aim of transforming cutting - edge science into novel therapies and diagnostics that directly benefit individuals affected by neurodegenerative diseases.

The study authors write that using the LSC17 score to single out high - risk patients predicted to have resistant disease «provides clinicians with a rapid and powerful tool to identify AML patients who are less likely to be cured by standard therapy and who could be enrolled in trials evaluating novel upfront or post-remission strategies.»

A number of these trials represent completely novel classes of therapy, such as employing fragments of RNA that interfere with problem genes or developing vaccines meant to quell drug addiction.

The findings hold promise for the development of novel targeted therapies with fewer harmful side effects.

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each patient.

Four people with paraplegia are able to voluntarily move previously paralyzed muscles as a result of a novel therapy that involves electrical stimulation of the spinal cord, according to a study funded in part by the National Institutes of Health and the Christopher & Dana Reeve Foundation.

Margaret Shupnik, PhD, a Professor of Medicine at UVA's School of Medicine who also worked with Jarjour's team says she hopes that the findings will prompt other researchers to develop novel therapies that regulate TLRs, and offer lupus patients the kind of treatment options that they currently don't have.

With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells.

So far, DARPA has released two calls for grant applications, with at least one more likely: The first, called SUBNETS (Systems - Based Neurotechnology for Emerging Therapies), asks researchers to develop novel, wireless devices, such as deep brain stimulators, that can cure neurological disorders such as posttraumatic stress (PTS), major depression, and chronic pain.

Findings of a three - year clinical trial led by University of Cincinnati (UC) transplant researchers suggest that a novel pre-operative drug therapy reduces antibodies in kidney patients with greater success than with traditional methods, with the potential to increase the patients» candidacy for kidney transplantation and decrease the likelihood of organ rejection.

Coupled with a review of these results by experts on a molecular tumor board, the opportunity exists to identify novel therapies that would target specific abnormalities,» notes senior author of the work, Shridar Ganesan, MD, PhD, associate director for translational science at Rutgers Cancer Institute and associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School.

Young and his colleagues found that twice - weekly infusions of this novel therapy were well tolerated and resulted in a low incidence of bleeding events in children with severe hemophilia A.

New studies from the Abramson Cancer Center of the University of Pennsylvania are providing fresh clues on potentially effective combinations with CAR T therapy in brain cancer as well as a novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cancer.

An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding episodes by 87 %.

In partnership with the Italian Cystic Fibrosis Research Foundation, we founded a CF animal Core Facility (CFaCore) as a platform for pre-clinical studies and for testing novel antibacterial or anti-inflammatory therapies.

A physician with a longstanding interest in gene therapy, Dr. High was formerly a Professor at the Perelman School of Medicine of the University of Pennsylvania, an Investigator of the Howard Hughes Medical Institute, and the Founding Director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, a Center focused on developing novel cell and gene - based therapies for genetic disease.

In my role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, I am developing novel therapies for patients with cancer.

In addition, the FDA will continue to work closely with industry to find other ways to aid in the effort to bring novel therapies to patients as quickly, and as safely, as possible.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

I - Stem, the Institute for Stem cell Therapy and Exploration of Monogenic Diseases, has signed an agreement with Swissbased healthcare company Roche to use I - Stem's technologies in discovering novel therapies to treat devastating central nervous system (CNS) diseases such as Alzheimer's, schizophrenia, depression and anxiety.

We are currently developing small molecule Nav1.1 activators that increase Nav1.1 currents and interneuron - dependent gamma oscillations in vitro and in vivo to develop novel therapies for conditions with impaired interneuron function, including AD and Dravet syndrome.

Gladstone was a great fit for me, especially with its background in developmental and translational biology and Bruce's research focus on cutting - edge technologies to model genetic disease and find novel therapies for treating them.

From founding one of the world's most successful high frequency trading organizations to advancing the power of stem cell therapies and regenerative medicine, Dr. Bosarge combines inventiveness with creative talent to bring novel ideas and products to the marketplace.

Scientists at the Gladstone Institutes are pursuing novel therapies to stop this cacophony in the brain with the goal of treating epilepsy, as well as seizure activity resulting from traumatic brain injury, stroke, or Alzheimer's disease.

A Multi-arm, Phase Ib, Open - Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm + Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Professor Ferner's research with national and international collaborators focuses on defining clinical phenotype in the neurofibromatoses, determining the natural history of optic pathway glioma and developing robust clinical and patient centred outcome measures for monitoring novel therapies.

Through understanding the biology of cancer cells and their interaction with the immune system we are able to discover and trial novel therapies to induce the immune system to detect and fight cancer cells.

In line with the objectives of the International Rare Disease Research Consortium (IRDiRC), we aim to develop novel tools that will allow to make more accurate diagnoses, predict the disease course and the efficacy of available treatments, and help developing new and better therapies for rare kidney diseases.

Novel studies are already underway with the goal of preventing and managing relapse in the context of CAR T - cell therapy.

GigaGen's proprietary approach delivers unprecedented insights into immune regulatory pathways and what causes them to fail, enabling a pipeline of novel antibody therapies for patients with cancer and immune deficiency diseases.

With her recent groundbreaking findings in the field of RNA - mediated regulation based on the CRISPR - Cas9 system, E. Charpentier has laid the foundation for the development of a novel, highly versatile and specific genome editing technology that is revolutionizing life sciences research and could open up whole new opportunities in biomedical gene therapies.

At Silence we are developing novel RNAi based therapies with the potential to transform patients» lives.

The Maharaj Institute has an FDA IND clinical trial protocol (08001 - BMSCTI) for investigating a novel cancer therapy using transfusions of white blood cells from healthy donors to patient with advanced solid tumors.

Across 20 years, I have published more than 150 clinical and translational publications with a focus on the cell biology of melanoma and immunology and patented eight novel therapies.

Peptide Receptor Radionuclide and Octreotide: A Novel Approach for Metastatic Tumor - Induced Osteomalacia JES May 3, 2017 Abilash Nair, Semanti Chakraborty, Pramila Dharmshaktu, Nikhil Tandon, Yashdeep Gupta, Rajesh Khadgawat, Puthiyaveettil Khadar Jabbar, Chandra Sekhar Bal, Shipra Agarwal, and Mohd Ashraf Ganie Octreotide can be used as an adjunctive therapy to increase phosphorus levels in patients with tumor - induced osteomalacia.

The first of what is planned to become an annual event, the evening began with six early - stage biotech companies pitching their technologies to the investors that can help make their novel therapies a reality.

This «humanized» mouse is susceptible to human liver infections and responds to human drug treatments, providing a new way to test novel therapies for debilitating human liver diseases and other diseases with liver involvement such as malaria.

We are actively forging strategic partnerships to accelerate the development of our novel therapies for patients with protein misfolding diseases.

In collaboration with Industry partners, his group has developed a novel non-human primate model to study viral dynamics and the nature of the SIV reservoir under potent anti-retroviral therapy.

The results of her project will help scientists develop novel therapies to target the regulatory proteins that cause CD47 overproduction in leukemia and other cancer stem cells, with the goal of restoring immunosurveillance and enabling the immune system to recognize and destroy these aberrant cancer cells.